NCT01871233

An Extended Access Program for Perampanel

• Status: No Longer Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: Eisai Inc. · Industry
• Sex: All
• Age: 12 Years – 70 Years
• Healthy volunteers: —

Summary

The Extended Access Program (EAP) is a managed access programme for Perampanel. The main objective of this EAP is to ensure that patients participating in studies E2007-A001-207, E2007-G000-307, or E2007-G000-235 continue to have access to perampanel until such time perampanel tablets become commercially available for the treatment of Partial Onset Seizures (POS) in the country in which they reside. This EAP will consist of 2 phases: * Screening: The patient will start the program once the Screening assessments are completed and the patient is qualified for participation. * Treatment: Additional assessments, physical examinations, and dosage changes will be clinically determined by the treating physician. Patients will enter this program on the same dose of perampanel that they were receiving at the end of their participation in previous study. Doses of perampanel and of concomitant anti-epileptic drugs (AEDs) can be adjusted (i.e., added,removed, or changed in dose) based on clinical judgment. Treatment will be prescribed as long as clinically appropriate according to the judgement of the treating physician and the approved Summary of Product Characteristics (SmPC). The program will complete in a staggered fashion, country by country, as and when perampanel becomes commercially available for the treatment of POS in each country.

Conditions

• Partial Onset Seizures

Interventions

Type	Name	Description
DRUG	Perampanel	Patients will enter this program on the same dose of perampanel that they were receiving at the end of their participation in Studies 207, 307, or 235. Doses of perampanel and of concomitant anti-epileptic drugs (AEDs) can be adjusted based on clinical judgment. A minimum daily dose permitted will be 12 mg per day. Treatment will be prescribed as long as clinically appropriate according to the judgment of the treating physician and the approved summary of Product Characteristics (SmPC). Tablets will be available in strengths of 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. Patients will be instructed to take their perampanel tablets once daily, by mouth, before bedtime, and with food.

Timeline

• First posted: 2013-06-06
• Last updated: 2020-04-16

Locations

78 sites across 21 countries: Argentina, Australia, Belgium, Canada, Chile, Czechia, Estonia, Finland, Greece, Hong Kong, Hungary, Israel, Italy, Latvia, Lithuania, Malaysia, Netherlands, Poland, Spain, Taiwan, Thailand